CC BY-NC-ND 4.0 · South Asian J Cancer 2019; 08(03): 139-144
DOI: 10.4103/sajc.sajc_343_18
Quadriplegia secondary to abiraterone-induced severe hypokalemia
Jignesh B. Rajvanshi
DNB Medical Oncology Resident, Department of Medical Oncology, Apollo CBCC Cancer Care, Ahmedabad, Gujarat
,
Manin D. Chaudhary
DNB Medical Oncology Resident, Department of Medical Oncology, Apollo CBCC Cancer Care, Ahmedabad, Gujarat
,
Priyanka D. Malekar
DNB Surgical Oncology Resident, Department of Medical Oncology, Apollo CBCC Cancer Care, Ahmedabad, Gujarat
,
Nitin K. Singhal
Consultant Surgical Oncology, Department of Medical Oncology, Apollo CBCC Cancer Care, Ahmedabad, Gujarat
,
Shirish S. Alurkar
Chief Director, Department of Medical Oncology, Apollo CBCC Cancer Care, Ahmedabad, Gujarat
› Institutsangaben
Financial support and sponsorship Nil.
Publikationsverlauf
Artikel online veröffentlicht:
21. Dezember 2020
© 2019. MedIntel Services Pvt Ltd. This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial-License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/.)
Thieme Medical and Scientific Publishers Pvt. Ltd.
A-12, 2nd Floor, Sector 2, Noida-201301 UP, India
-
References
-
1 de Bono JS, Logothetis CJ, Molina A, Fizazi K, North S, Chu L, et al. Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med 2011;364:1995-2005.
-
2 Fizazi K, Scher HI, Molina A, Logothetis CJ, Chi KN, Jones RJ, et al. Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: Final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study. Lancet Oncol 2012;13:983-92.
-
3 Fizazi K, Tran N, Fein L, Matsubara N, Rodriguez-Antolin A, Alekseev BY, et al. Abiraterone plus prednisone in metastatic, castration-sensitive prostate cancer. N Engl J Med 2017;377:352-60.
-
4 James ND, de Bono JS, Spears MR, Clarke NW, Mason MD, Dearnaley DP, et al. STAMPEDE Investigators abiraterone for prostate cancer not previously treated with hormone therapy. N Engl J Med 2017;377:338.
